Vascular endothelial growth factor (VEGF) inhibition is a rational therapeutic approach in breast cancer because VEGF plays an important role in tumour blood vessel growth, tumour progression and metastasis. Bevacizumab is a recombinant humanised antibody targeted at VEGF. As VEGF is overexpressed in ...
11 However, for women with moderate- and high-penetrance mutations, they are comparable to the LE gains for adjuvant chemotherapy: 1.4 years for 45-year-old women with node-positive and 0.9 years for those with node-negative breast cancer.48 The LE gains from secondary cancer prevention ...
To estimate the risk for contralateral breast cancer in members of BRCA1- and BRCA2-positive families and to determine predictive risk factors. A retrospective, multicenter, cohort study was performed from 1996 until 2008 and comprised 2,020 women with unilateral breast cancer (index patients, n ...
The spouse of another man had an adverse psychological reaction to the disclosure of his positive result. Two, already suffering from prostate cancer, were phenocopies and paternal lineage transmission was unexpectedly determined in another. Risk was removed from 33 offspring and confirmed for 56. ...
D. et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98, 1569–1577 (2003). PubMed Google Scholar Goffin, J. R. et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis...
The data from the Münster survey suggest that there is little regret regarding the decision to undergo testing and that the vast majority of women would undergo the test again. However, women with positive findings experienced more problems than women with negative results. They were less ...
Among the 23 families examined, two families had members with ovarian cancers, three had members with prostate cancers, and one had a pancreatic cancer. However, none of these families was positive for theBRCA1 orBRCA2 mutation. Histopathologically, we observed a prevalence of histological grade ...
Mike BittnerJeffrey TrentNature GeneticsDuggan DJ, Hedenfalk IA, Chen Y, Bittner M, Borg A, Trent JM. Mi- croarray analysis discriminates BRCA2 mutation-positive from BRCA1 and sporadic breast cancer patient tumour biopsies. Nat Genet 1999; 23 (Supl): 43....
BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) encode for tumor suppressor proteins which are critical regulators of the Homologous Recombination (HR) pathway, the most precise and important DNA damage response mechanism. Dysfunctional HR
Among the 879 patients analyzed (924 assays), 130 had positive mutations inBRCA1(3.1%),BRCA2(8.6%), andPALB2(5.2%), with a total of 14.8% having genetic alterations. Co-occurrence was noted betweenBRCA1/BRCA2,BRCA1/PALB2,andBRCA2/PALB2mutations. InBRCA1-mutated samples, only p.K65...